Fianlimab + cemiplimab phase 3 (first-line melanoma)
A second LAG-3 blocker failed to beat pembrolizumab alone, a warning that the Opdualag result is not automatically a class effect.
Regeneron reported that the trial missed its primary PFS endpoint; the high-dose combination improved median PFS numerically by 5.1 months but not significantly. Differences from RELATIVITY-047 include the comparator (pembrolizumab rather than nivolumab), the antibody, and dosing. The adjuvant fianlimab phase 3 continues.
Pages like this
not linked directly; found by shared links- TrialRELATIVITY-098
Shares Caution: LAG-3 blockade outside active disease, LAG-3, Melanoma and the tag failure.
- TrialEMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9
Shares Cemiplimab, Regeneron, PD-1.
- ProductRelatlimab + nivolumab
Shares Caution: LAG-3 blockade outside active disease, RELATIVITY-047, LAG-3, PD-1.
- ProductEpacadostat
Shares Pembrolizumab, Melanoma and the tag failure.
- TrialLEAP-002
Shares Pembrolizumab and the tag failure.
- ProductADU-S100 (MIW815)
Shares Melanoma and the tag failure.
- ProductBempegaldesleukin
Shares Melanoma and the tag failure.
- TrialIMpassion131
Shares Pembrolizumab and the tag failure.